Skip to main content
. 2023 Oct 26;41(1):198–214. doi: 10.1007/s12325-023-02705-9

Fig. 2.

Fig. 2

Example of a pretreatment protocol prior to initiation of vosoritide (ACH, achondroplasia; ENT, ear, nose, and throat)